|Mr. Matthew Craig Kapusta||CEO, CFO & Exec. Director||908.63k||459.12k||1972|
|Dr. Alexander E. Kuta Ph.D.||Exec. VP of Operations||610.61k||2.42M||1960|
|Prof. Hugo Katus||Chairman of Scientific Advisory Board and Managing Director of UniQure-Germany||N/A||N/A||N/A|
|Mr. Christian Klemt||Chief Accounting Officer||N/A||N/A||1973|
|Mr. David Cerveny||Chief Legal Officer, Gen. Counsel & Sec.||N/A||N/A||1967|
|Ms. Maria E. Cantor||Chief Communications Officer||N/A||N/A||1968|
|Dr. Tamara Tugal Ph.D., MBA||Bus. Devel. Director||N/A||N/A||N/A|
|Mr. James Brady||Chief HR Officer||N/A||N/A||N/A|
|Mr. Jonathan Garen M.S.||Chief Bus. Officer||N/A||N/A||1966|
|Mr. Ricardo Dolmetsch Ph.D.||Pres of R&D||N/A||N/A||1969|
uniQure N.V., a gene therapy company, engages in the development and commercialization of treatments for patients suffering from genetic and other diseases in the Netherlands. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease; AMT-060, which is in Phase I/II clinical trial for the treatment of hemophilia B; AMT-180, an one-time intravenously-administered gene therapy candidate, which is in preclinical stage for the treatment of hemophilia A; and AMT-190, an IV-administered adeno-associated virus 5-based gene therapy for the treatment of Fabry disease. In addition, it engages in developing AMT-150, a gene therapy candidate for the treatment of Spinocerebellar Ataxia Type 3 disease. The company has collaboration and license agreements with Bristol Myers-Squibb Company; Gen-X; and Synpromics Limited. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
uniQure N.V.’s ISS Governance QualityScore as of December 1, 2020 is 2. The pillar scores are Audit: 2; Board: 4; Shareholder Rights: 3; Compensation: 5.